Lisa DiMartino

Lisa DiMartino

Auto-generated profile, based on publicly available information

Lisa DiMartino

Peter O'Donnell School of Public Health, UT Southwestern Medical Center, Dallas, TX

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2018 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
LDLisa D. DiMartino
Lisa D. DiMartino
ABAna A. Baumann
Ana A. Baumann
LHLewis L. Hsu
Lewis L. Hsu
JKJulie Kanter
Julie Kanter
VGVictor R. Gordeuk
Victor R. Gordeuk
FCfor the Sickle Cell Disease Implementation Consortium
for the Sickle Cell Disease Implementation Consortium
Click on the article title to read more.

4 November 2021 in Journal of Pain and Symptom Management
Verified
Journal Article
Closed access
LDLisa DiMartino
Lisa DiMartino
TMThomas Miano
Thomas Miano
KWKathryn Wessell
Kathryn Wessell
BBBuck Bohac
Buck Bohac
LHLaura C. Hanson
Laura C. Hanson

1 January 2018 in Journal of Palliative Medicine
Verified
Journal Article
Closed access
LDLisa D. DiMartino
Lisa D. DiMartino
BWBryan J. Weiner
Bryan J. Weiner
LHLaura C. Hanson
Laura C. Hanson
MWMorris Weinberger
Morris Weinberger
SBSarah A. Birken
Sarah A. Birken
JTJustin G. Trogdon
Justin G. Trogdon
Prior research indicates that hospice and palliative care delivered in outpatient settings are associated with reduced hospital readmissions for cancer patients. However, little is known about how inpatient palliative care affects readmissions in oncology. To examine associations among inpatient palliative care consultation, hospice use (discharge), and 30-day readmissions among patients with solid tumor cancers. We identified all live discharges from a large tertiary cancer hospital between 2010 and 2016. Palliative care consult data were abstracted from medical charts and linked to hospital encounter data. Propensity scores were used to match palliative care consult to usual care encounters. Modified Poisson regression models estimated adjusted relative risk (aRR) and 95% confidence intervals (CI) of 30-day readmissions and hospice discharge. We compared predicted probabilities of readmission for palliative care consultation with hospice discharge, without hospice discharge, and usual care. Of 8085 eligible encounters, 753 involved a palliative care consult. The likelihood of having a 30-day readmission did not differ between palliative care consult and usual care groups (p > 0.05). However, the palliative care consult group was more likely than usual care to have a hospice discharge (aRR = 4.09, 95% CI: 3.07-5.44). The predicted probability of 30-day readmission was lower when palliative care consultation was combined with hospice discharge compared to usual care or consultation with discharge to nonhospice postacute care (p < 0.001). The effect of inpatient palliative care on readmissions in oncology is largely driven by hospice enrollment. Strategies that combine palliative care consultation with hospice discharge may decrease hospital readmissions and improve cancer care quality.

14 July 2020 in JMIR Research Protocols
Verified
Journal Article
Open access
JHJane S Hankins
Jane S Hankins
NSNirmish Shah
Nirmish Shah
LDLisa DiMartino
Lisa DiMartino
DBDonald Brambilla
Donald Brambilla
MFMaria Fernández
Maria Fernández
SCSickle Cell Disease Implementation Consortium
Sickle Cell Disease Implementation Consortium
Background: Hydroxyurea prevents disease complications among patients with sickle cell disease (SCD). Although its efficacy has been endorsed by the National Health Lung and Blood Institute evidence-based guidelines, its adoption is low, both by patients with SCD and providers. Mobile health (mHealth) apps provide benefits in improving medication adherence and self-efficacy among patients with chronic diseases and have facilitated prescription among medical providers. However, mHealth has not been systematically tested as a tool to increase hydroxyurea adherence nor has the combination of mHealth been assessed at both patient and provider levels to increase hydroxyurea utilization.Objective: This study aims to increase hydroxyurea utilization through a combined two-level mHealth intervention for both patients with SCD and their providers with the goals of increasing adherence to hydroxyurea among patients and improve hydroxyurea prescribing behavior among providers.Methods: We will test the efficacy of 2 mHealth interventions to increase both patient and provider utilization and knowledge of hydroxyurea in 8 clinical sites of the NHLBI-funded Sickle Cell Disease Implementation Consortium (SCDIC). The patient mHealth intervention, InCharge Health, includes multiple components that address memory, motivation, and knowledge barriers to hydroxyurea use. The provider mHealth intervention, Hydroxyurea Toolbox (HU Toolbox), addresses the clinical knowledge barriers in prescribing and monitoring hydroxyurea. The primary hypothesis is that among adolescents and adults with SCD, adherence to hydroxyurea, as measured by the proportion of days covered (the ratio of the number of days the patient is covered by the medication to the number of days in the treatment period), will increase by at least 20% after 24 weeks of receiving the InCharge Health app, compared with their adherence at baseline. As secondary objectives, we will (1) examine the change in health-related quality of life, acute disease complications, perceived health literacy, and perceived self-efficacy in taking hydroxyurea among patients who use InCharge Health and (2) examine potential increases in the awareness of hydroxyurea benefits and risks, appropriate prescribing, and perceived self-efficacy to correctly administer hydroxyurea therapy among SCD providers between baseline and 9 months of using the HU Toolbox app. We will measure the reach, adoption, implementation, and maintenance of both the InCharge Health and the HU Toolbox apps using the reach, effectiveness, adoption, implementation, and maintenance framework and qualitatively evaluate the implementation of both mHealth interventions.Results: The study is currently enrolling study participants. Recruitment is anticipated to be completed by mid-2021.Conclusions: If this two-level intervention, that is, the combined use of InCharge Health and HU Toolbox apps, demonstrates efficacy in increasing adherence to hydroxyurea and prescribing behavior in patients with SCD and their providers, respectively, both apps will be offered to other institutions outside the SCDIC through a future large-scale implementation-effectiveness study.Trial Registration: ClinicalTrials.gov NCT04080167; https://clinicaltrials.gov/ct2/show/NCT04080167International Registered Report Identifier (IRRID): DERR1-10.2196/16319

13 July 2010 in Clinical Cardiology
Verified
Journal Article
Open access
PDF file
LDLisa D. DiMartino
Lisa D. DiMartino
ASAlisa M. Shea
Alisa M. Shea
AHAdrian F. Hernandez
Adrian F. Hernandez
LCLesley H. Curtis
Lesley H. Curtis
Background: Most information about the use of guideline‐recommended therapies for heart failure reflects what occurred at discharge after an inpatient stay.Hypothesis: Using a nationally representative, community‐dwelling sample of elderly Medicare beneficiaries, we examined how the use of angiotensin‐converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and β‐blockers has changed and factors associated with their use.Methods: Using data from the Medicare Current Beneficiary Survey cost and use files matched with Medicare claims data, we identified beneficiaries for whom a diagnosis of heart failure was reported between January 1, 2000, and December 31, 2004. Data on medications prescribed during the year of cohort entry were based on patient self‐report. We used multivariable logistic regression to explore relationships between the use of ACE inhibitors/ARBs and β‐blockers and patient demographic characteristics.Results: From 2000 through 2004, the use of ARBs increased from 12% to 19%, and the use of β‐blockers increased from 30% to 41%. The use of ACE inhibitors remained constant at 45%. Beneficiaries who reported having prescription drug insurance coverage were 32% more likely than other beneficiaries to have filled a prescription for an ACE inhibitor or ARB and 26% more likely to have filled a prescription for a β‐blocker.Conclusions: Although the use of guideline‐recommended therapies for heart failure has increased, it remains suboptimal. Copyright

1 July 2018 in Health Care Management Review
Verified
Journal Article
Closed access
LDLisa D. DiMartino
Lisa D. DiMartino
SBSarah A. Birken
Sarah A. Birken
LHLaura C. Hanson
Laura C. Hanson
JTJustin G. Trogdon
Justin G. Trogdon
ACAlecia S. Clary
Alecia S. Clary
BWBryan J. Weiner
Bryan J. Weiner
Background: The implementation science literature has contributed important insights regarding the influence of formal policies and practices on health care innovation implementation, whereas informal implementation policies and practices have garnered little attention. The broader literature suggests that informal implementation policies and practices could also influence innovation use. Purpose: We used the Organizational Theory of Innovation Implementation to further understand the role of formal and informal implementation policies and practices as determinants of implementation effectiveness. We examined their role within the context of initiatives to increase palliative care consultation in inpatient oncology. Methods: We used a case study design in two organizational settings within one academic medical center: medical and gynecologic oncology. We completed semistructured interviews with medical (n = 12) and gynecologic (n = 10) oncology clinicians using questions based on organizational theory. Quantitative data assessed implementation effectiveness, defined as aggregated palliative care consult rates within oncology services from 2010 to 2016. Four palliative care clinicians were interviewed to gain additional implementation context insights. Results: Medical oncology employed multiple formal policies and practices including training and clinician prompting to support palliative care consultation and a top-down approach, yet most clinicians were unaware of the policies and practices, contributing to a weak implementation climate. In contrast, gynecologic oncology employed one formal policy (written guideline of criteria for initiating a consult) but also relied on informal policies and practices, such as spontaneous feedback and communication; they adopted a bottom-up approach, contributing to broader clinician awareness and strong implementation climate. Both services exhibited variable, increasing consult rates over time. Practice Implications: Informal policies and practices may compensate or substitute for formal policies and practices under certain conditions (e.g., smaller health care organizations). Further research is needed to investigate the role of formal and informal policies and practices in shaping a strong and sustainable implementation climate and subsequent effective innovation implementation.